0001209191-15-071559.txt : 20150921 0001209191-15-071559.hdr.sgml : 20150921 20150921132342 ACCESSION NUMBER: 0001209191-15-071559 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150918 FILED AS OF DATE: 20150921 DATE AS OF CHANGE: 20150921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PORTOLA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001269021 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 270 EAST GRAND AVENUE, SUITE 22 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-244-6864 MAIL ADDRESS: STREET 1: 270 EAST GRAND AVENUE, SUITE 22 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dier Mardi CENTRAL INDEX KEY: 0001574591 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35935 FILM NUMBER: 151116986 MAIL ADDRESS: STREET 1: PORTOLA PHARMACEUTICALS, INC. STREET 2: 270 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-09-18 0 0001269021 PORTOLA PHARMACEUTICALS INC PTLA 0001574591 Dier Mardi C/O PORTOLA PHARMACEUTICALS, INC. 270 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Executive VP and CFO Common Stock 2015-09-18 4 M 0 2934 5.10 A 2934 D Common Stock 2015-09-18 4 M 0 978 5.10 A 3912 D Common Stock 2015-09-18 4 M 0 5000 9.00 A 8912 D Common Stock 2015-09-18 4 S 0 8912 55.00 D 0 D Stock Option (Right to Buy) 5.10 2015-09-18 4 M 0 2934 0.00 D 2009-02-25 2019-02-25 Common Stock 2934 0 D Stock Option (Right to Buy) 5.10 2015-09-18 4 M 0 978 0.00 D 2009-06-09 2019-06-09 Common Stock 978 0 D Stock Option 9.00 2015-09-18 4 M 0 5000 0.00 D 2010-02-24 2020-02-24 Common Stock 5000 0 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2015, as amended on May 11, 2015. These shares were sold in a single transaction at a price of $55.000. /s/ Mike Ouimette, as Attorney-In-Fact 2015-09-18